Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV

Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 11,507.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,937,112 shares of the company’s stock after acquiring an additional 6,877,348 shares during the period. Assenagon Asset Management S.A. owned 1.00% of Roivant Sciences worth $150,535,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Rubric Capital Management LP lifted its stake in Roivant Sciences by 14.7% in the second quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the period. State Street Corp boosted its stake in Roivant Sciences by 4.8% during the second quarter. State Street Corp now owns 19,773,480 shares of the company’s stock worth $222,847,000 after acquiring an additional 911,827 shares in the last quarter. Two Seas Capital LP boosted its stake in Roivant Sciences by 4.6% during the second quarter. Two Seas Capital LP now owns 10,598,040 shares of the company’s stock worth $119,440,000 after acquiring an additional 461,733 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Roivant Sciences by 18.0% in the third quarter. Dimensional Fund Advisors LP now owns 9,308,710 shares of the company’s stock worth $140,839,000 after purchasing an additional 1,423,074 shares during the period. Finally, Marshall Wace LLP grew its holdings in Roivant Sciences by 316.5% in the third quarter. Marshall Wace LLP now owns 3,978,001 shares of the company’s stock worth $60,187,000 after purchasing an additional 3,022,851 shares during the period. 64.76% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ROIV shares. Leerink Partners upped their price objective on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. HC Wainwright raised their target price on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Sanford C. Bernstein started coverage on Roivant Sciences in a research note on Friday. They set an “outperform” rating and a $35.00 price target on the stock. Finally, Citigroup increased their price target on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $27.93 on Tuesday. The company has a 50-day moving average price of $26.03 and a 200-day moving average price of $21.42. The stock has a market capitalization of $19.99 billion, a P/E ratio of -23.87 and a beta of 1.17. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $30.33.

Insider Buying and Selling

In related news, insider Frank Torti sold 1,400,000 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the transaction, the insider owned 13,736,547 shares of the company’s stock, valued at $376,656,118.74. The trade was a 9.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mayukh Sukhatme sold 1,018,995 shares of the company’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $21.71, for a total value of $22,122,381.45. Following the sale, the insider owned 20,267,429 shares of the company’s stock, valued at $440,005,883.59. This trade represents a 4.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,187,954 shares of company stock worth $159,440,314 over the last three months. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.